Disease / Etiology
|
Preferred
|
Alternative
|
Comments
|
Infective Endocarditis
|
Native valve, Non IVDU, prosthetic valve
Strep viridans
Other Streptococci
|
MIC < 0.125ug/ml
Benzylpenicillin 50,000 units/kg/dose IV q6H for 4 weeks (6 weeks for
prothestic)
MIC > 0.125 to 2
ug/ml
ADD Gentamicin 1 mg/kg/dose IV q8H for 2 weeks (6 weeks for prothestic)
|
MIC < 0.125ug/ml
Ampicillin 75mg/kg/dose IV
q6H for 4 weeks (6 weeks for
prothestic)
OR
Ceftriaxone 100mg/kg/dose IV q24H for
4 weeks (6 weeks for prothestic)
MIC > 0.125 to 2
ug/ml
ADD Gentamicin 1 mg/kg/dose IV q8H for 2 weeks (6 weeks for prothestic)
|
At least 3 sets of blood cultures from different sites before
empiric therapy.
Penicillin allergy:
Vancomycin 15mg/kg/dose IV q8H for 4 weeks (6 weeks for prothestic)
+ Gentamicin 1 mg/kg IV q8H for 2 weeks (6 weeks for prothestic)
|
Native valve
Left sided endocarditis:
Staphylococcus aureus (MSSA, MRSA)
|
For MSSA IE:
Cloxacillin 50 mg/kg/dose IV q6H for 4-6 weeks
For MRSA IE:
Vancomycin 15mg/kg/dose IV q8H for 4 - 6 weeks
|
For MSSA IE:
Cefazolin 30mg/kg/dose IV q8H for 4-6 weeks
|
|
Native valve
Right sided endocarditis:
Staphylococcus aureus (MSSA,
MRSA)
|
For MSSA IE:
Cloxacillin 50 mg/kg/dose IV q6H for 4 weeks
For MRSA IE:
Vancomycin
15mg/kg/dose IV q8H for 4-6 weeks
|
|
|
Prosthetic valve
endocarditis:
Staphylococcus aureus (MSSA)
|
Cloxacillin 50 mg/kg/dose IV q6H for >6 weeks
AND
Rifampicin 20 mg/kg/day PO q8H for >6 weeks
AND
Gentamicin 1 mg/kg/dose IV q8H for 2 weeks
|
|
Rifampicin
has better penetration. However to avoid the development of resistance, it
should be started after 3-5 days of effective initial cloxacillin therapy
and/or once the bacteraemia has been cleared.
|
Prosthetic valve endocarditis:
Staphylococcus aureus (MRSA)
|
Vancomycin 20 mg/kg/dose
IV q8H for > 6 weeks
AND
Rifampicin 20 mg/kg/day
PO q8H for >6 weeks
AND
Gentamicin 1 mg/kg/dose IV q8H for 2 weeks
|
|
Rifampicin
has better penetration. However to avoid the development of resistance, it
should be started after 3-5 days of effective initial vancomycin therapy
and/or once the bacteraemia has been cleared.
|
Pericarditis (Purulent)
|
Staph aureus
Strep pneumoniae
Haemophilus influenzae
Other Streptococci
Gram negative bacteria
|
Cloxacillin 50
mg/kg/dose IV q6H for 4 - 6 weeks
AND
Gentamicin 1 mg/kg/dose
IV q8H for 2 weeks
|
Vancomycin 15/kg/dose
IV q8H for 4 - 6 weeks
AND
Gentamicin 1 mg/kg/dose
IV q8H for 2 weeks
|
Duration: minimum 4
weeks
Early surgical consult for possibly intervention. Ceftriaxone / Cefotaxime
may be considered in place of Gentamicin.
|
Rheumatic Fever
|
Post infectious
sequelae of Group A strep infection
|
Benzylpenicillin 50,000
units/kg/dose IV q6H for 10 - 14 days
Followed by Penicillin V prophylaxis:
<5 years old 125 mg q12H
>5 years old 250 mg q12H
|
|
Penicillin allergy:
Erythromycin: 15mg/kg/dose PO q6H for 10 - 14 days
Followed by Erythromycin 15 mg/kg PO q12H
|
Pacemaker /
Defibrillator & Ventricular Assist Device Related Infection
|
S aureus
S epidermidis
Aerobic gram negative bacilli
Fungal
|
Vancomycin
15/kg/dose IV q8h for 6 weeks
+ Gentamicin 1 mg/kg/dose IV q8h for 2 weeks
|
|
IV to PO switch
possible after clinical improvement.
Fungal infection rare. For proven fungal infections Amphotericin B or
Voriconazole equally effective.
|
Infective Endocarditis
Prophylaxis Guideline for Dental Procedure
|
Viridans group
streptococci
|
Oral:
Amoxicillin 50 mg/kg/dose
(60 minutes before procedure)
Parenteral (IV):
Ampicillin 50 mg/kg/dose
(30 minutes before procedure)
|
Allergy to penicillin/ ampicillin
Oral:
Clindamycin 20 mg/kg/dose
(60 minutes before procedure)
Parenteral (IV):
Clindamycin 20 mg/kg/dose
(30 minutes before procedure)
|
Cardiac conditions in
which prophylaxis for dental procedures is recommended.
1. Prosthetic cardiac valve
2. Native valvular
heart disease including established rheumatic heart disease 3. Previous IE 4. Unrepaired cyanotic CHD, including palliative shunts and conduits 5. Completely repaired CHD with prosthetic material or device, for the
first 6 months after the procedure 6. Repaired CHD with residual defects at the site or adjacent to the site
of a prosthetic patch or device (which inhibit endothelialization) 7. Cardiac transplantation recipients who develop cardiac valvulopathy
|